Literature DB >> 20030561

Bone marrow-derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity.

Goang-Won Cho1, Min-Young Noh, Hyun Young Kim, Seong-Ho Koh, Kyung-Suk Kim, Seung Hyun Kim.   

Abstract

Human bone marrow stromal cells (BM-SCs) possess the potential to differentiate, self-renew, and produce diverse trophic/growth factors and are an excellent cell therapy tool for degenerative diseases. However, they exhibit different therapeutic efficacies, depending on the health status and age of the cell donor. Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron death in the central nervous system. In this study, we isolated BM-SCs from 11 ALS patients and characterized their potential secretory capacity of neurotrophic factors. We identified significant reductions in the expression of Oct-4 and Nanog , and in the trophic factors ANG, FGF -2, HGF, IGF-1, PIGF, SDF-1alpha , TGF-beta, and VEGF, but not in BDNF or ECGF. Migration of ALS-SCs was reduced, although the cells expressed the same markers for human mesenchymal phenotypes. These data suggest that ALS-SCs have diminished capacity as trophic mediators and may have reduced beneficial effects in cell therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20030561     DOI: 10.1089/scd.2009.0453

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  16 in total

Review 1.  Concise review: adult mesenchymal stem cells, adult neural crest stem cells, and therapy of neurological pathologies: a state of play.

Authors:  Virginie Neirinckx; Cécile Coste; Bernard Rogister; Sabine Wislet-Gendebien
Journal:  Stem Cells Transl Med       Date:  2013-03-13       Impact factor: 6.940

Review 2.  Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future.

Authors:  J Simon Lunn; Stacey A Sakowski; Eva L Feldman
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

3.  ALS-associated mutation SOD1G93A leads to abnormal mitochondrial dynamics in osteocytes.

Authors:  Huan Wang; Jianxun Yi; Xuejun Li; Yajuan Xiao; Kamal Dhakal; Jingsong Zhou
Journal:  Bone       Date:  2017-10-10       Impact factor: 4.398

Review 4.  Stem cell technology for neurodegenerative diseases.

Authors:  J Simon Lunn; Stacey A Sakowski; Junguk Hur; Eva L Feldman
Journal:  Ann Neurol       Date:  2011-09       Impact factor: 10.422

5.  Functional Restoration of Amyotrophic Lateral Sclerosis Patient-Derived Mesenchymal Stromal Cells Through Inhibition of DNA Methyltransferase.

Authors:  Youn Seo Oh; Seung Hyun Kim; Goang-Won Cho
Journal:  Cell Mol Neurobiol       Date:  2015-07-26       Impact factor: 5.046

Review 6.  Muscle-Bone Crosstalk in Amyotrophic Lateral Sclerosis.

Authors:  Jingsong Zhou; Jianxun Yi; Lynda Bonewald
Journal:  Curr Osteoporos Rep       Date:  2015-10       Impact factor: 5.096

7.  Neuroprotective and Angiogenic Effects of Bone Marrow Transplantation Combined With Granulocyte Colony-Stimulating Factor in a Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Yasuyuki Ohta; Makiko Nagai; Kazunori Miyazaki; Nobuhito Tanaka; Hiromi Kawai; Takafumi Mimoto; Nobutoshi Morimoto; Tomoko Kurata; Yoshio Ikeda; Tohru Matsuura; Koji Abe
Journal:  Cell Med       Date:  2011-10-01

8.  Immunomodulatory Properties of Bone Marrow Mesenchymal Stem Cells from Patients with Amyotrophic Lateral Sclerosis and Healthy Donors.

Authors:  Eliska Javorkova; Nicole Matejckova; Alena Zajicova; Barbora Hermankova; Michaela Hajkova; Pavla Bohacova; Jan Kossl; Magdalena Krulova; Vladimir Holan
Journal:  J Neuroimmune Pharmacol       Date:  2018-09-21       Impact factor: 4.147

Review 9.  Autologous stem cells in neurology: is there a future?

Authors:  Johannes P J M de Munter; Erik C Wolters
Journal:  J Neural Transm (Vienna)       Date:  2012-11-23       Impact factor: 3.575

10.  Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application.

Authors:  Chen Benkler; Daniel Offen; Eldad Melamed; Lana Kupershmidt; Tamar Amit; Silvia Mandel; Moussa B H Youdim; Orly Weinreb
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.